Myelodysplastic disorders

References 

1. Jaffe ES, Harris NL, Stein H, Vardiman JW. World Health Organization classification of tumours: pathology and genetics. Tumours of haematopoietic and lymphoid tissues. Oxford: Oxford University Press; 2001;
2. Williamson PJ, Kruger AR, Reynolds PJ, et al. Establishing the incidence of myelodysplastic syndrome. Br J Haematol. 1994;87:743–745
   • MEDLINE
   • CrossRef
3. Fenaux P, Morel P, Lai JL. Cytogenetics in myelodysplastic syndromes. Semin Hematol. 1996;33:139–149
   • MEDLINE
4. Bowen D, Calligan D, Jowitt S, et al. Guidelines for the diagnosis and therapy of adult myelodysplastic syndrome. Br J Haematol. 2003;120:187–200
   • MEDLINE
   • CrossRef
5. Hellstrom-Lindberg E, Negrin R, Stein R, et al. Erythroid response to treatment with G-CSF plus erythropoietin for the anaemia of patients with myelodysplastic syndrome: proposal for a predictive model. Br J Haematol. 1997;99:344–351
   • MEDLINE
6. List A, Dewald G, Bennett J, et al. Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. N Eng J Med. 2006;355:1456–1465
7. Fenaux P, Mufti GJ, Santini V, et al. Azacitidine (AZA) treatment prolongs overall survival (OS) in higher-risk MDS patients compared with conventional care regimens (CCR): results of the AZA-001 Phase III study. Blood. 2007;110:817
8. Martino R, Iacobelli S, Brand R, et al. Retrospective comparison of reduced-intensity conditioning and conventional high-dose conditioning for allogeneic hematopoietic stem cell transplantation using HLA-identical sibling donors in myelodysplastic syndromes. Blood. 2006;108:836–846
   • MEDLINE
   • CrossRef
9. Moldrem JJ, Leifer E, Bahceci E, et al. Anti-thymocyte globulin for treatment of bone marrow failure associated with myelodysplastic syndrome. Ann Intern Med. 2002;137:156–163
10. Greenberg P, Cox C, LeBeau MM, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood. 1997;89:2079–2088
    • MEDLINE